Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 17Pancreatic Neoplasms 11Carcinoma, Hepatocellular 10Colonic Neoplasms 7Rectal Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Cholangiocarcinoma 4Breast Neoplasms 4Prostatic Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Thrombocytosis 1Somatostatinoma 1Sarcoma 1Resectable Intrahepatic Cholangiocarcinoma 1Recurrence 1

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Disulfides × Gastrointestinal × Clear all
NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
57 enrolled 13 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT04164069 2024-12-27

Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
9 enrolled
Gastrointestinal

Bile Duct Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡